Authorized purpose: HeartFocus v1.1.1 guides trained medical professionals in acquiring ten standard adult 2D transthoracic echocardiographic views using compatible ultrasound systems, with live probe guidance, image-quality feedback and recording assistance for subsequent clinical interpretation.
Clinical role
Acquisition guidance and image-quality/recording assistance
Images and patients
Ultrasound · Heart/Cardiovascular
Key limitation
Keep in mind: Adult acquisition aid requiring trained users and qualified interpretation. Clinical-study image quality varied by view, particularly subcostal IVC. PCCP allows specified compatibility changes after validation; it does not establish that every current probe/OS was tested in the initial v1.1.1 study.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: HeartFocus v1.1.1 guides trained medical professionals in acquiring ten standard adult 2D transthoracic echocardiographic views using compatible ultrasound systems, with live probe guidance, image-quality feedback and recording assistance for subsequent clinical interpretation.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Heart/Cardiovascular Input: Live adult 2D-TTE ultrasound stream; initial compatibility lists Clarius PAHD3 wireless, PAHD, PAL and Clarius Ultrasound Scanner Software. Views: PLAX, PSAX-AV/MV/PM, A4C/A5C/A2C/A3C, SC-4C and SC-IVC.
Who uses it?Intended users: Medical professionals trained in ultrasound basics and HeartFocus use, including trained nurses, physicians and sonographers
What does the software produce?Output: Probe-position guidance cues, color-coded diagnostic-quality feedback, Auto Record, Best-Effort Record and recorded-clip quality information; acquired exams are available for clinician review and transfer.
What is its most important limitation?Key limitation: Adult acquisition aid requiring trained users and qualified interpretation. Clinical-study image quality varied by view, particularly subcostal IVC. PCCP allows specified compatibility changes after validation; it does not establish that every current probe/OS was tested in the initial v1.1.1 study.
Clinical takeaway. Clinical role: HeartFocus v1.1.1 guides trained medical professionals in acquiring ten standard adult 2D transthoracic echocardiographic views using compatible ultrasound systems, with live probe guidance, image-quality feedback and recording assistance for subsequent clinical interpretation.
Evidence takeaway. Evidence from the reviewed source record: The initial Clarius/v1.1.1 evidence supports trained-user image acquisition with expert interpretation. Current Butterfly family features and commercial terms cannot be used as original-study results.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
HeartFocus v1.1.1 guides trained medical professionals in acquiring ten standard adult 2D transthoracic echocardiographic views using compatible ultrasound systems, with live probe guidance, image-quality feedback and recording assistance for subsequent clinical interpretation.
Probe-position guidance cues, color-coded diagnostic-quality feedback, Auto Record, Best-Effort Record and recorded-clip quality information; acquired exams are available for clinician review and transfer.
Adult acquisition aid requiring trained users and qualified interpretation. Clinical-study image quality varied by view, particularly subcostal IVC. PCCP allows specified compatibility changes after validation; it does not establish that every current probe/OS was tested in the initial v1.1.1 study.
The initial Clarius/v1.1.1 evidence supports trained-user image acquisition with expert interpretation. Current Butterfly family features and commercial terms cannot be used as original-study results.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The initial Clarius/v1.1.1 evidence supports trained-user image acquisition with expert interpretation. Current Butterfly family features and commercial terms cannot be used as original-study results.
A single disease-detection sensitivity is not established by the reviewed acquisition-quality studies.
Reported specificity
93.9%
FDA source
Exact FDA submission
Checked 2026-08-13
Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.
EndpointProportion of clips saved with Best-Effort Record judged of diagnostic image quality in the prospective acquisition study
Population240 adults aged at least 22 at one French and one US center; eight nurse operators, five blinded cardiologist assessors; recorded clips graded using ACEP scale
Tested versionHeartFocus v1.1.1 with Clarius in K242807 clinical study
DesignManufacturer prospective multicenter paired acquisition study; trained novice nurses compared with experts on the same ultrasound system, five blinded cardiologist reviewers
Population240 clinically indicated echocardiography patients aged at least 22; 120 France and 120 US
Scopeexact submission
Tested versionHeartFocus v1.1.1 with Clarius
Samplen=240
Sites2
IndependenceSponsor or vendor study
K242807
Eight nurses acquired ten views; four primary endpoints assessed examination suitability for visual LV size/function, RV size and nontrivial effusion evaluation. Secondary quality outcomes were descriptive and varied by view; not an autonomous diagnosis study.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
Pricing is recorded, but no exact-product procurement price with a stated offer scope is published in the reviewed sources.
Public pricing
The current HeartFocus family pricing page displays $695 per license/year/probe or $1,800 per license/three years/probe for up to five licenses, with unlimited users; enterprise six-plus licenses require a quote.
Product family
Checked 2026-09-05
Current family offer, not an exact v1.1.1/Clarius quote. The page shows a dollar sign but no ISO currency; no normalized price observation is emitted. Hardware, tax and local contract inclusions require confirmation.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Live adult 2D-TTE ultrasound stream; initial compatibility lists Clarius PAHD3 wireless, PAHD, PAL and Clarius Ultrasound Scanner Software. Views: PLAX, PSAX-AV/MV/PM, A4C/A5C/A2C/A3C, SC-4C and SC-IVC.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Connects to a compatible ultrasound system's image stream; collected exams can be transferred using DICOM protocols.
Scope: Exact FDA submission. Specific PACS/RIS/EHR configuration and later ultrasound integrations need confirmation.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The FDA summary describes an offline application with medical data stored locally on the tablet and no data transfer to a DESKi-controlled server for its functions.
Scope: Exact FDA submission. Corrects the baseline's nonspecific Hybrid label using the exact summary; current device configuration remains separately scoped.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Probe-position guidance cues, color-coded diagnostic-quality feedback, Auto Record, Best-Effort Record and recorded-clip quality information; acquired exams are available for clinician review and transfer.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Probe-position guidance cues, color-coded diagnostic-quality feedback, Auto Record, Best-Effort Record and recorded-clip quality information; acquired exams are available for clinician review and transfer.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA summary describes an offline application with medical data stored locally on the tablet and no data transfer to a DESKi-controlled server for its functions.
Exact FDA submission
Checked 2026-09-05
Corrects the baseline's nonspecific Hybrid label using the exact summary; current device configuration remains separately scoped.
DESKi's coordinated vulnerability disclosure policy, scoped to DESKi products and services, provides security researcher prerequisites (no patient-safety risk, written permission before testing, coordinated public disclosure timing), an encrypted reporting channel (security@deski.ai with a public PGP key), and handling expectations for vulnerability reports.
Vendor-wide
Checked 2026-10-27
Vendor CVD policy naming DESKi on the HeartFocus product site (heartfocus.ai), which uses the deski.ai contact domain. Exact-release scope is not established.
DESKi's coordinated vulnerability disclosure policy, scoped to DESKi products and services, states acknowledgement of receipt within two business days, investigation and risk analysis of reported vulnerabilities, and a summary of findings provided to the submitter.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The policy names DESKi products and services generally and does not scope these commitments to any specific product release; exact-release scope is not established. This is an intake and response-handling commitment; it states no uptime, drift or continuous-monitoring claims.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-05Last searched
21Fields reviewed
12Source classes checked
0Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
Stored DESKi-sponsored PROSPECTIVE EVALUATION OF HEARTFOCUS metadata screened. Live registry page exposed only an application shell, so trial details and exact release linkage were not established; no registry result promoted. Clinical-study abstraction is sourced to the FDA summary only. Stored PubMed array empty. The current discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor pricing, literature index, trial registry, stored candidate metadata, stored recall candidates, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Deski HeartFocus reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Authorized purpose: Guides medical professionals acquiring ten standard 2D transthoracic echocardiographic views in adults requiring a cardiac ultrasound examination; acquired images require qualified clinical interpretation.
Ligence Heart is a fully automated software platform that processes, analyses and makes measurements on acquired transthoracic cardiac ultrasound images, automatically producing a full report with measurements of several key cardiac structural and functional parameters. The data produced by this software is intended to be used to support qualified cardiologists or sonographers for clinical decision making. Ligence Heart is indicated for use in adult patients. Ligence Heart has not been validated for the assessment of congenital heart disease, valve disease, pericardial disease, and/or intra-cardiac lesions (e.g., tumors, thrombi). Limitations: Poor image capture will lead to poor annotations and subsequent measurements. Multiple image quality algorithms are used to filter out images of poor quality. Our software complements good patient care and does not exempt the user from the responsibility to provide supervision, clinically review the patient, and make appropriate clinical decisions. If no gender is present, female referenced guideline values will be used for conclusions. If Body Surface Area (BSA) is not present, indexed values cannot be provided. During image acquisition, inappropriate use of the echo machine, use of non-cardiac ultrasound probes, or use of suboptimal settings (e.g., gain, contrast, depth) may lead to lower accuracy of the software. Ligence Heart has not been validated in patients with prosthetic or surgically altered cardiac valves, implantable intracardiac devices, or irregular (non-sinus) rhythm; these conditions may affect automated measurement accuracy.
Authorized purpose: PVAD IQ supports qualified-physician clinical decision support by identifying the aortic annulus and PVAD inlet, calculating their mean distance, and identifying clips acceptable for this measurement.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.